Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

Core Insights - Eli Lilly and Company has announced the appointment of two new Executive Committee members and the expansion of existing leaders' roles to enhance its ambitious pipeline and improve patient access to medicines [1][6]. Leadership Changes - Carole Ho, M.D., has been appointed as executive vice president and president of Lilly Neuroscience, bringing over 20 years of biopharmaceutical experience [2]. - Adrienne Brown has been promoted to executive vice president and president of Lilly Immunology, having held various leadership roles at Lilly for over 20 years [3]. - Daniel Skovronsky, M.D., Ph.D., will expand his role as chief scientific and product officer, overseeing research and development for Cardiometabolic Health, Immunology, and Neuroscience [4]. - Jacob Van Naarden will also take on an expanded role, incorporating corporate business development under his leadership [5]. Strategic Vision - The company aims to leverage its transformed research engine and expanded production capacity to enhance access to care and affordability, with a focus on driving growth and improving patient outcomes [6].